Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data
Samantha Noteboom(Université de Bordeaux), Martijn D. Steenwijk(Amsterdam Neuroscience), Eva Strijbis(Amsterdam University Medical Centers), Zoé L. E. van Kempen(Amsterdam Neuroscience), Hugo Vrenken(Amsterdam Neuroscience), Menno M. Schoonheim(Amsterdam Neuroscience), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), Bas Jasperse(Vrije Universiteit Amsterdam), Elisa Colato(Amsterdam Neuroscience), Eline M. E. Coerver(Amsterdam Neuroscience)
Cited by 5
Related Papers
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
|The Lancet Neurology|2021|646
Loss of ‘Small-World’ Networks in Alzheimer's Disease: Graph Analysis of fMRI Resting-State Functional Connectivity
|PLoS ONE|2010|621
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
|Human Molecular Genetics|2008|479
Deep gray matter volume loss drives disability worsening in multiple sclerosis
|Annals of Neurology|2018|441
Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment
|Neurobiology of Aging|2011|396